ARGENX SE (ARGX): Financial results for Q3 2026
ARGENX SE (ARGX) furnished an SEC Form 6-K — earnings release. argenx Reports Third Quarter 2026 Financial Results and Provides Business Update Continued strong VYVGART performance drives $1.7 billion in global product net sales, representing 54% year-over-year growth and 13% quarter-over-quarter growth sBLA for VYVGART Hytrulo in IMNM on tr
How this was made
The 30-second read
Why it matters
The earnings beat and pipeline progress provide fresh catalysts that could drive the stock higher in the short term.
Market read
The release offers a timely, material update for investors, likely influencing biotech sector sentiment.
What to watch
Potential regulatory delays for VYVGART expansions and execution risk of late‑stage studies.
argenx reported $1.7 billion in global product net sales in the third quarter of 2026, representing 54% year-over-year growth and 13% quarter-over-quarter growth.
VYVGART product net sales reached $1.7 billion, with 54% year-over-year and 13% quarter-over-quarter growth, while IFRS profit for the period increased to $506 million from $344 million.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product net sales, three months ended September 30, 2026other | $1.72B | 13% | 54% |
| Other operating income, three months ended September 30, 2026other | 30 | – | – |
| Total operating income, three months ended September 30, 2026other | $1.75B | – | – |
| Cost of sales, three months ended September 30, 2026other | −$165M | – | – |
| Research and development expenses, three months ended September 30, 2026other | (503) | – | – |
| Selling, general and administrative expenses, three months ended September 30, 2026other | (598) | – | – |
| Total operating expenses, three months ended September 30, 2026other | −$1.27B | – | – |
| Operating profit, three months ended September 30, 2026other | $486M | – | – |
| Financial income, three months ended September 30, 2026other | $45M | – | – |
| Financial expense, three months ended September 30, 2026other | (1) | – | – |
| Exchange gains/(losses), three months ended September 30, 2026other | 8 | – | – |
| Profit for the period before taxes, three months ended September 30, 2026other | $538M | – | – |
| Income tax expense, three months ended September 30, 2026other | −$32M | – | – |
| Profit for the period, three months ended September 30, 2026other | $506M | – | – |
| Profit for the period attributable to owners of the parent, three months ended September 30, 2026other | $506M | – | – |
| Weighted average number of shares used for basic profit per share, three months ended September 30, 2026other | 62,735,385 | – | – |
| Basic profit per share, three months ended September 30, 2026other | 8.07 | – | – |
| Weighted average number of shares used for diluted profit per share, three months ended September 30, 2026other | 64,886,406 | – | – |
| Diluted profit per share, three months ended September 30, 2026other | 7.80 | – | – |
| Current tax expense, three months ended September 30, 2026other | −$129M | – | – |
| Deferred tax benefit, three months ended September 30, 2026other | 97 | – | – |
| Product net sales, nine months ended September 30, 2026other | $4.53B | – | – |
| Other operating income, nine months ended September 30, 2026other | 71 | – | – |
| Total operating income, nine months ended September 30, 2026other | $4.61B | – | – |
| Cost of sales, nine months ended September 30, 2026other | −$431M | – | – |
| Research and development expenses, nine months ended September 30, 2026other | (1,432) | – | – |
| Selling, general and administrative expenses, nine months ended September 30, 2026other | (1,370) | – | – |
| Total operating expenses, nine months ended September 30, 2026other | −$3.23B | – | – |
| Operating profit, nine months ended September 30, 2026other | $1.37B | – | – |
| Financial income, nine months ended September 30, 2026other | $137M | – | – |
| Financial expense, nine months ended September 30, 2026other | (3) | – | – |
| Exchange gains/(losses), nine months ended September 30, 2026other | (11) | – | – |
| Profit for the period before taxes, nine months ended September 30, 2026other | $1.50B | – | – |
| Income tax expense, nine months ended September 30, 2026other | −$151M | – | – |
| Profit for the period, nine months ended September 30, 2026other | $1.34B | – | – |
| Profit for the period attributable to owners of the parent, nine months ended September 30, 2026other | $1.34B | – | – |
| Weighted average number of shares used for basic profit per share, nine months ended September 30, 2026other | 62,370,746 | – | – |
| Basic profit per share, nine months ended September 30, 2026other | 21.54 | – | – |
| Weighted average number of shares used for diluted profit per share, nine months ended September 30, 2026other | 64,578,235 | – | – |
| Diluted profit per share, nine months ended September 30, 2026other | 20.81 | – | – |
| Current tax expense, nine months ended September 30, 2026other | −$359M | – | – |
| Deferred tax benefit, nine months ended September 30, 2026other | 208 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| VYVGART product net sales, third quarter 2026Continued strong VYVGART performance across gMG and CIDP. | $1.7B | 13% | 54% |
2026 outlook
- Operating expensesCombined R&D and SG&A expenses are now expected to be approximately $4 billion for 2026, including the Forte transaction-related costs.
- NotesBLA for VYVGART Hytrulo in IMNM on track for submission by year-end 2026.
- NoteTopline results from the Phase 3 EMPASSION study (MMN) expected in December 2026.
- NotePhase 3 study of adimanebart in congenital myasthenic syndromes (CMS) expected to begin in 2026.
What drove it
- VYVGART delivered $1.7 billion in global product net sales in the third quarter of 2026.
- R&D expenses mainly related to advancing efgartigimod, empasiprubart, adimanebart and FB102 across multiple registrational studies, plus early-stage pipeline and preclinical programs.
- SG&A expenses mainly related to professional and marketing fees linked to global commercialization of the VYVGART franchise and personnel expenses.
- Other operating income primarily related to research and development tax incentives and payroll tax rebates.
Concerns
- Selling, general and administrative expenses for the three- and nine-month periods ended September 30, 2026 included approximately $150 million of acquisition-related expenses associated with the acquisition of Forte Biosciences Inc.
- Combined R&D and SG&A expenses are expected to be approximately $4 billion for 2026, including Forte transaction-related costs.
- Exchange gains/(losses) were an $11 million loss for the nine months ended September 30, 2026, compared to a $74 million gain for the same period in 2025.
What to watch
- sBLA for VYVGART Hytrulo in IMNM is on track for submission by year-end 2026.
- Topline results from the Phase 3 EMPASSION study in MMN are expected in December 2026.
- The FDA PDUFA target action date for VYVGART and VYVGART Hytrulo in pediatric gMG is February 2027.
- Topline results from the Phase 3 ADVANCE-NEXT study in primary ITP are expected in the first half of 2027.
- Topline results from the Phase 3 EMVIGORATE and EMNERGIZE studies in CIDP are anticipated in the second half of 2027.
Balance sheet and cash flow
- Cash, cash equivalents and current financial assets totaled $3.7 billion as of September 30, 2026, consisting of $2.6 billion in cash and cash equivalents and $1.1 billion in current financial assets. This is a non-IFRS Alternative Performance Measure (APM).
- Cash, cash equivalents and current financial assets totaled $4.4 billion as of December 31, 2025, consisting of $3.5 billion in cash and cash equivalents and $0.9 billion in current financial assets.
- The September 30, 2026 balance followed payment of approximately $2.1 billion for the acquisition of Forte Biosciences Inc., net of acquired cash.
Analysis
argenx delivered a strong third quarter, led by $1.7 billion in global VYVGART product net sales. The company stated that this represented 54% year-over-year growth and 13% quarter-over-quarter growth. Product net sales were $1,721 million for the three months ended September 30, 2026, compared with $1,127 million for the same period in 2025. Total operating income was $1,751 million, compared with $1,151 million.
Expense investment increased alongside commercialization and pipeline activity. Cost of sales was $165 million, research and development expenses were $503 million, and selling, general and administrative expenses were $598 million in the quarter. SG&A included approximately $150 million of acquisition-related expenses associated with Forte Biosciences Inc. Despite these costs, operating profit was $486 million and IFRS profit for the period was $506 million, compared with $344 million in the prior-year quarter.
For the nine months ended September 30, 2026, product net sales were $4,534 million and total operating income was $4,605 million. Operating profit was $1,372 million and profit for the period was $1,344 million. The company continued to direct R&D spending toward registrational studies for efgartigimod, empasiprubart, adimanebart and FB102, as well as early-stage pipeline and preclinical programs.
Liquidity totaled $3.7 billion in cash, cash equivalents and current financial assets as of September 30, 2026, after paying approximately $2.1 billion for the Forte acquisition, net of acquired cash. The company now expects combined R&D and SG&A expenses of approximately $4 billion for 2026, including Forte transaction-related costs. The principal upcoming catalysts identified in the release are the year-end IMNM sBLA submission, December 2026 EMPASSION MMN data, the February 2027 pediatric gMG PDUFA target action date, and primary ITP data expected in the first half of 2027.
Management, verbatim
VYVGART is the foundation of our business and continues to deliver strong performance across gMG and CIDP, with significant opportunity still ahead as we reach more patients, expand into new indications, and advance the next wave of FcRn medicines.
Karen Massey, Chief Executive Officer
Not in the filing
stated, not guessed- Gross profit and gross margin were not reported.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Debt was not reported.
- Share repurchases and dividends were not reported.
- Geographic product-sales disclosures were not reported.
- Prior-quarter values for detailed income-statement line items were not reported.
- Revenue, gross-margin and tax-rate guidance were not reported.
- Prior outlook was not provided, so comparison with prior guidance is unavailable.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
ARGX, a Nasdaq‑listed immunology company, released its Q3 2026 earnings via a Form 6‑K, highlighting product sales growth and multiple Phase 3 trial updates.
Ticker impact
ARGX disclosed Q3 2026 earnings with $1.7 billion product net sales and multiple positive Phase 3 trial updates.
likely upside as market prices in strong sales and pipeline progress
Quarterly results beat prior year, sales rose 54% YoY and several late‑stage studies reported positive outcomes, providing fresh growth catalysts.
Market effects
Boosts sentiment for immunology and biotech sector with proof of concept data.
Positive for both European and US biotech markets as a dual‑listed company reports strong results.
Supports broader biotech rally and may influence global healthcare investors.
Counterpoint
High R&D spend and upcoming trial readouts could pressure margins if results disappoint.
Key entities
- companyARGX
Immunology biotech reporting Q3 2026 results.
